EGGALL · Use of microbial transglutaminase to reduce egg protein allergenicity
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2009-06-15 → 2011-06-14
- Финансиране от ЕС
- 172 435 €
- Участници
- 1
- Схема
- MC-IEF
Линиите свързват координатора с партньорите.
Накратко на български
Ензимът микробна трансглутаминаза се тества за промяна на протеините овалумин и овомукоид в яйчения белтък, за да се намали способността им да предизвикват алергии. Това помага за създаването на по-безопасни храни за хора с хранителни алергии в Европейския съюз.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Use of microbial transglutaminase to reduce egg protein allergenicity
The project aimed to investigate whether microbial transglutaminase (mTG) mediated modification could be used to reduce the immunogenic properties of the proteins ovomucoid and ovalbumin present in egg white. The structural stability of the proteins to thermal processing and in vitro digestion was investigated before and after enzymatic modification with mTG. Using a multidisciplinary approach, we developed strategies for enzymatically modifying the major egg allergens ovalbumin and ovomucoid with mTG to reduce the immunoreactivity of these proteins. Introducing this enzyme for modifying egg white proteins will enable the rational development of healthier foods with improved functionality that can also combat the deleterious health effects resulting from the current allergy crisis in the EU. At the host institution (IFR) Concetta Valeria L. Giosafatto has, in particular, carried out experiments using in vitro digestion under physiologically relevant conditions following established IFR protocols. Both mTG-modified samples and the corresponding controls, treated in the absence of the enzyme, were submitted to in vitro digestion. Simulated gastric-followed by duodenal digestion was performed with / without the physiological surfactant phosphatidylcholine (PC). The results demonstrate feasible approaches for modifying the proteins by means of the crosslinking enzyme to control (reduce) the rate of proteolysis and hence potentially induce physiological responses that could moderate food consumption. The project initially looked at the modification of the egg white proteins, ovalbumin and ovomucoid, by means of the enzyme mTG. Before the enzymatic modification, the proteins were firstly purified and their secondary structure characterised by means of Circular Dichroism (CD) and Infrared Spectroscopy (FTIR). These studies were then extended to investigate the effects of the enzymatic modification on digestion carried out under both gastric and duodenal conditions and on rheological properties. EGGALL has made use of rheological tools to investigate the effect of mTG on the viscoelastic properties of egg protein gels. Secondly simulated digestion experiments under gastric and duodenal conditions were carried out on unmodified and mTG-modified samples that had undergone a range of processing conditions. Furthermore, by using an enzymatic approach, based on the enzyme Peptide-N4-(acetyl-b-glucosaminyl) asparagines amidase (PNGase F), Dr Giosafatto was able to fully deglycosylate the ovomucoid protein. The important finding of a synergism between sulfhydryl reagent, surfactants and heating suggests that similar approaches could also be applied for the deglycosylation different glycoproteins, in which the glycans are responsible of their immunological properties. This is generating renewed scientific interest due to the growing social and economic consequences of the allergy crisis in the developed world. The design of healthier foods to control the allergy is a top priority in the EU: it is estimated that treating allergy and related conditions takes up to 7 % of the total healthcare budget within the EU. EGGALL has shown through the application of fundamental science that an enzymatic approach, based on the enzyme mTG can change the digestibility and rheological properties of proteins.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The aim of this proposal is to investigate whether transglutaminase mediated modification can be used to reduce the allergenic potential of ovomucoid and ovalbumin present in egg white. The rising levels of allergies are a serious cause for concern within the European Union, especially in children. Allergic diseases affect between 10-20% of the population and usually start during infancy, childhood or adolescence, and up to 5% children have food allergy (www.foodallergy.org). Food allergies are more prevalent in children, due to an immature gastrointestinal epithelial membrane barrier, allowing more proteins through the barrier and into circulation. Allergy to egg is one of the major allergies in infants and young children. This project will involve studies that could provide important information about how to manage egg proteins hypersensitivity. Modification of proteins by transglutaminase is thought to have beneficial effects on their allergenic properties. Through improved understanding of this effect, we aim to develop strategies for enzymatically modifying the major egg allergens such as ovalbumin and ovomucoid with transglutaminase to reduce the immunoreactivity of these proteins. To achieve this we require a multidisciplinary approach, bringing together the following key skills and expertise: · Biochemistry skills and expertise are required to modify ovalbumin and ovomucoid using transglutaminase and to evaluate the antigenicity (ability of a protein or a peptide to bind an antibody) and the allergenicity of the modified forms. · Physiological expertise is required to define and develop accurate models of protein digestion which are representative of the in vivo situation. In particular models that are relevant to the infant gut where egg allergy is developed. · Immunological skill to use both polyclonal and monoclonal antibodies to study the persistence of potential epitopes through simulated digestion.
Оригинален текст от CORDIS (на английски).
Участници
- QUADRAM INSTITUTE BIOSCIENCE · NorwichКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз
